← Leaderboards
Isabella Maria Grumbach
University Of Iowa
$6,457,677
Attributed
$8,823,030
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2011–25$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,823,030 · 3
VA$0 · 2
By mechanism
R01$8,823,030 · 3
I01$0 · 1
I21$0 · 1
Top collaborators
- Randy H. Kardon6 shared
- William H Thiel4 shared
Most similar at University Of Iowa
Same institution · by research overlap
- Joseph J Cullen$5,964,157
- Garry R Buettner$6,434,018
- Bryan Allen$2,697,856
- Melissa Ann Fath$775,635
- Thomas A Weingeist$124,957
Others in their field
Top investigators on “Blood Vessels”
- Sonia M Thomas · Research Triangle Institute$353,402,726
- Tracy L Nolen · Research Triangle Institute$353,402,726
- Charles Decarli · University Of California At Davis$66,498,201
- Josef Coresh · New York University School Of Medicine$63,693,760
- Sterling C Johnson · St. Joseph'S Hospital And Medical Center$62,000,770
- Robert P Kimberly · University Of Alabama At Birmingham$56,093,149
Research focus
Blood VesselsIn VivoPreventReportingInjuryBasePathway InteractionsMitochondriaResponseMolecularProductionInnovationProgramsPhosphotransferasesCalmodulinVascular DiseasesSignal TransductionNovel TherapeuticsReactive Oxygen SpeciesNovel StrategiesMissionMediatingEndotheliumCardiovascular System
Grant awards (40)
Leveraging the mitochondrial regulator MIRO1 to prevent neointimal hyperplasia$482,748
R01 · FY2025 · HL · contact PI
Leveraging the mitochondrial regulator MIRO1 to prevent neointimal hyperplasia$62,540
R01 · FY2025 · HL · contact PI
Leveraging mitochondrial function to combat radiation therapy-induced microvascular disease$0
I01 · FY2025 · VA · contact PI
Leveraging the mitochondrial regulator MIRO1 to prevent neointimal hyperplasia$612,903
R01 · FY2024 · HL · contact PI
Laser speckle flowgraphy as early indicator of microvasculopathy in radiation-induced vision loss$489,521
R01 · FY2024 · EY · contact PI
Leveraging mitochondrial function to combat radiation therapy-induced microvascular disease$0
I01 · FY2024 · VA · contact PI
Leveraging the mitochondrial regulator MIRO1 to prevent neointimal hyperplasia$625,411
R01 · FY2023 · HL · contact PI
Laser speckle flowgraphy as early indicator of microvasculopathy in radiation-induced vision loss$489,521
R01 · FY2023 · EY · contact PI
Leveraging mitochondrial function to combat radiation therapy-induced microvascular disease$0
I01 · FY2023 · VA · contact PI
Leveraging the mitochondrial regulator MIRO1 to prevent neointimal hyperplasia$625,411
R01 · FY2022 · HL · contact PI
Laser speckle flowgraphy as early indicator of microvasculopathy in radiation-induced vision loss$474,836
R01 · FY2022 · EY · contact PI
Leveraging mitochondrial function to combat radiation therapy-induced microvascular disease$0
I01 · FY2022 · VA · contact PI
Leveraging mitochondrial function to combat radiation therapy-induced microvascular disease$0
I01 · FY2022 · VA · contact PI
Laser speckle flowgraphy as early indicator of microvasculopathy in radiation-induced vision loss$474,835
R01 · FY2021 · EY · contact PI
Mitochondrial CaMKII drives smooth muscle migration and neointimal hyperplasia$438,352
R01 · FY2021 · HL · contact PI
Laser speckle flowgraphy as early indicator of microvasculopathy in radiation-induced cognitive decline$386,208
R01 · FY2021 · EY · contact PI
Leveraging mitochondrial function to combat radiation therapy-induced microvascular disease$0
I01 · FY2021 · VA · contact PI
Laser speckle flowgraphy as early indicator of microvasculopathy in radiation-induced vision loss$489,521
R01 · FY2020 · EY · contact PI
Mitochondrial CaMKII drives smooth muscle migration and neointimal hyperplasia$438,352
R01 · FY2020 · HL · contact PI
Mitochondrial CAMKII in smooth muscle as key regulator of hypertension and vascular remodeling$0
I01 · FY2020 · VA · contact PI
Mitochondrial CaMKII drives smooth muscle migration and neointimal hyperplasia$438,352
R01 · FY2019 · HL · contact PI
Mitochondrial CAMKII in smooth muscle as key regulator of hypertension and vascular remodeling$0
I01 · FY2019 · VA · contact PI
Mitochondrial CaMKII drives smooth muscle migration and neointimal hyperplasia$438,352
R01 · FY2018 · HL · contact PI
Mitochondrial CAMKII in smooth muscle as key regulator of hypertension and vascular remodeling$0
I01 · FY2018 · VA · contact PI
Mitochondrial CAMKII in smooth muscle as key regulator of hypertension and vascular remodeling$0
I01 · FY2017 · VA · contact PI
CaMKII as a regulator of diabetic retinopathy$0
I21 · FY2017 · VA · contact PI
CaMKII regulates key mechanisms of vascular response to injury in vivo$377,500
R01 · FY2016 · HL · contact PI
Calmodulin kinase II inhibition as novel molecular treatment of hypertension$0
I01 · FY2016 · VA · contact PI
CaMKII as a regulator of diabetic retinopathy$0
I21 · FY2016 · VA · contact PI
CaMKII regulates key mechanisms of vascular response to injury in vivo$371,837
R01 · FY2015 · HL · contact PI
CaMKII as a regulator of diabetic retinopathy$0
I21 · FY2015 · VA · contact PI
Calmodulin kinase II inhibition as novel molecular treatment of hypertension$0
I01 · FY2015 · VA · contact PI
CaMKII regulates key mechanisms of vascular response to injury in vivo$369,950
R01 · FY2014 · HL · contact PI
Calmodulin kinase II inhibition as novel molecular treatment of hypertension$0
I01 · FY2014 · VA · contact PI
CaMKII regulates key mechanisms of vascular response to injury in vivo$359,380
R01 · FY2013 · HL · contact PI
Calmodulin kinase II inhibition as novel molecular treatment of hypertension$0
I01 · FY2013 · VA · contact PI
CaMKII regulates key mechanisms of vascular response to injury in vivo$377,500
R01 · FY2012 · HL · contact PI
CaMKII mediates vascular smooth cell hypertrophy and hypertension$0
I01 · FY2012 · VA · contact PI
CaMKII mediates vascular smooth cell hypertrophy and hypertension$0
I01 · FY2011 · VA · contact PI
CaMKII mediates vascular smooth cell hypertrophy and hypertension$0
I01 · FY2011 · VA · contact PI